CoChat

Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: A randomized, placebo‐controlled study

Open access
Berman, Marius, Erman, Arie, Ben‐Gal, Tuvia, Dvir, Dan, Georghiou, Georgios P., Stamler, Alon, Vered, Yaffa, Vidne, Bernardo A., Aravot, Dan · 2004 · Clinical Cardiology
Cited by 88

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Background: The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure. Hypothesis: The purpose of the present double‐blind, placebo‐controlled, randomized study was to assess the effect of CoQ10 on patients with end‐stage heart failure and to determine if CoQ10 can improve the pharmacological bridge to heart transplantation. Methods: A prospective double‐blind design was used. Thirty‐two patients with end‐stage heart failure awaiting heart transplantation were randomly allocated to receive either 60 mg U/day of Ultrasome™‐‐‐CoQ10 (special preparation to increase intestinal absorption) or placebo for 3 months. All patients continued their regular medication regimen. Assessments included anamnesis with an extended questionnaire based partially on the Minnesota Living with Heart Failure Questionnaire, 6‐min walk test, blood tests for atrial natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography. Results: Twenty‐seven patients completed the study. The study group showed significant improvement in the 6‐min walk test and a decrease in dyspnea, New York Heart Association (NYHA) classification, nocturia, and fatigue. No significant changes were noted after 3 months of treatment in echocardiography parameters (dimensions and contractility of cardiac chambers) or ANF and TNF blood levels. Conclusion: The administration of CoQ10 to heart transplant candidates led to a significant improvement in functional status, clinical symptoms, and quality of life. However, there were no objective changes in echo measurements or ANF and TNF blood levels. Coenzyme Q10 may serve as an optional addition to the pharmacologic armamentarium of patients with end‐stage heart failure. The apparent discrepancy between significant clinical improvement and unchanged cardiac status requires further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/clc.4960270512

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 88

Metadata

Authors
Berman, M., Erman, A., Ben‐Gal, T., Dvir, D., Georghiou, G. P., Stamler, A., Vered, Y., Vidne, B. A., & Aravot, D.
Venue
Clinical Cardiology
Publisher
Wiley
Published
2004-05
Volume
27
Issue
5
Pages
295-299
ISSN
  • 0160-9289 (ISSN-L)
  • 1932-8737
OpenAlex
W1872960871
Cited by
88
References
1
FWCI
1.97
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: A randomized, placebo‐controlled study. https://app.cochat.ai/papers/10.1002/clc.4960270512
The paper
Berman, M., Erman, A., Ben‐Gal, T., Dvir, D., Georghiou, G. P., Stamler, A., Vered, Y., Vidne, B. A., & Aravot, D. (2004). Coenzyme Q10 in patients with end‐stage heart failure awaiting cardiac transplantation: A randomized, placebo‐controlled study. Clinical Cardiology. https://doi.org/10.1002/clc.4960270512

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.